As previously reported, Wells Fargo upgraded Veeva to Overweight from Equal Weight with a price target of $229, up from $211. The firm sees a path to double-digit revenue growth returning for Commercial Cloud and expects Veeva to fully defend its CRM turf with its top 25 pharma clients. Wells expects CRM replatforming and data asset benefits to accrue beyond 2026, thus not materially impacting near-term Wells and consensus estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VEEV: